Find a Doctor

Dr. Brian Andrew Van Tine

Washington University
Oncology, Internal Medicine
Male
Practicing approx. 16 years

Bio


Brian Van Tine is an Oncologist and an Internal Medicine specialist in Saint Louis, Missouri. Dr. Van Tine is highly experienced in treating patients with Rhabdoid Tumor Predisposition Syndrome. He has been an author on 93 peer reviewed articles and participated in 449 clinical trials in the past 15 years. He is licensed to treat patients in MO.

Contact

Saint Louis, MO 63110, US

Latest Advances


  • Condition: Epithelioid Sarcoma
  • Journal: The Lancet. Oncology
  • Treatment Used: Tazemetostat
  • Number of Patients: 62
  • Published —
This study evaluated the safety and effectiveness of Tazemetostat, an oral selective EZH2 inhibitor, in patients with epithelioid sarcoma.
  • Condition: Soft Tissue Sarcoma
  • Journal: JAMA
  • Treatment Used: Doxorubicin plus Olaratumab
  • Number of Patients: 509
  • Published —
This study evaluated the effectiveness of doxorubicin plus olaratumab for patients with advanced or metastatic soft tissue sarcoma.
  • Condition: Synovial Sarcoma (SS)
  • Journal: Journal for immunotherapy of cancer
  • Treatment Used: Adoptive Transfer of NY-ESO-1 SPEAR T Cells
  • Number of Patients: 42
  • Published —
These studies addressed the immunological mechanisms of response and resistance in patients with synovial sarcoma (SS) treated with NY-ESO-1 SPEAR T-cells.
  • Condition: Cetuximab-Resistant Human Papillomavirus (HPV)-Unrelated Head and Neck Cancer
  • Journal: The Lancet. Oncology
  • Treatment Used: Palbociclib and Cetuximab
  • Number of Patients: 62
  • Published —
This study established the proportion of patients achieving an objective response with palbociclib and cetuximab in recurrent or metastatic head and neck squamous-cell carcinomas (HNSCCs).
  • Condition: Soft tissue sarcoma (STS)
  • Journal: Journal of geriatric oncology
  • Treatment Used: Pharmacotherapy
  • Number of Patients: 640
  • Published —
The study researched the use of doxorubicin versus doxorubicin plus evofosfamide for patients with soft tissue sarcoma.
  • Condition: Metastatic Soft-Tissue Sarcoma
  • Journal: Cancer
  • Treatment Used: Gemcitabine, Docetaxel, and Ontuxizumab
  • Number of Patients: 209
  • Published —
This study tested the safety and efficacy of using a combination gemcitabine, docetaxel, and ontuxizumab chemotherapy to treat patients with metastatic soft-tissue sarcoma.
  • Condition: Metastatic and Unresectable Soft Tissue Sarcoma
  • Journal: Cancer medicine
  • Treatment Used: 13-deoxy, 5-iminodoxorubicin (GPX-150)
  • Number of Patients: 0
  • Published —
In this study, researchers evaluated the safety and effectiveness of 13-deoxy, 5-iminodoxorubicin (GPX-150) for the treatment of metastatic and inoperable soft tissue sarcoma.
  • Condition: Desmoid tumors
  • Journal: The New England journal of medicine
  • Treatment Used: Sorafenib
  • Number of Patients: 87
  • Published —
This study evaluated sorafenib for advanced and refractory desmoid tumors.
  • Condition: Soft Tissue Sarcoma in the Elderly
  • Journal: Annals of oncology : official journal of the European Society for Medical Oncology
  • Treatment Used: Trabectedin
  • Number of Patients: 577
  • Published —
In this study, researchers evaluated the safety and effectiveness of trabectedin for the treatment of soft tissue sarcoma in the elderly.
  • Condition: ALK-Positive Tumors (Excluding Non-Small-Cell Lung Cancer )
  • Journal: American journal of hematology
  • Treatment Used: Crizotinib
  • Number of Patients: 44
  • Published —
This study evaluated objective responses in patients with ALK-positive advanced malignancies other than non-small-cell lung cancer (NSCLC) who were to receive a starting dose of crizotinib 250 mg twice daily.

Clinical Trials


Clinical Trial
  • Status: Not yet recruiting
  • Phase: Phase 2
  • Intervention Type: Drug
  • Participants: 10
  • Start Date: May 31, 2021
A Pilot Study of 89Zr-Trastuzumab PET/CT in Subjects With Previously Treated HER2-Positive Solid Tumors Scheduled to Receive Treatment With MT-5111
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 2
  • Intervention Type: Drug
  • Participants: 105
  • Start Date: January 5, 2021
A Randomized Phase II Trial of Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma
Clinical Trial
  • Status: Recruiting
  • Phase: N/A
  • Intervention Type: Radiation, Procedure
  • Participants: 60
  • Start Date: September 22, 2020
A Trial of Palliative Lattice Stereotactic Body Radiotherapy (SBRT) for Patients With Sarcoma, Thoracic, Abdominal, and Pelvic Cancers
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 2
  • Intervention Type: Drug
  • Participants: 60
  • Start Date: September 9, 2020
A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Chondrosarcoma and Clear Cell Sarcoma
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 2
  • Intervention Type: Other, Drug, Biological
  • Participants: 90
  • Start Date: September 4, 2020
A Multicenter Phase II Trial of Paclitaxel With and Without Nivolumab in Taxane Naive, and Nivolumab and Cabozantinib in Taxane Pretreated Subjects With Angiosarcoma
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 1/Phase 2
  • Intervention Type: Drug
  • Participants: 33
  • Start Date: March 4, 2020
A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults With Relapsed, Recurrent, or Refractory Synovial Sarcoma
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 1/Phase 2
  • Intervention Type: Drug
  • Participants: 34
  • Start Date: January 22, 2020
A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults With Relapsed, Recurrent, or Refractory Desmoplastic Small Round Cell Tumor
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 2
  • Intervention Type: Other, Drug
  • Participants: 72
  • Start Date: January 14, 2020
A Phase II Study of Cabozantinib and Temozolomide in Patients With Unresectable or Metastatic Leiomyosarcoma and Other Soft Tissue Sarcomas
Clinical Trial
  • Status: Recruiting
  • Phase: N/A
  • Intervention Type: Other
  • Participants: 50
  • Start Date: October 31, 2019
Rehabilitation and Quality of Life Assessment for Soft Tissue Sarcoma Treated With Radiotherapy and Surgery
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 2
  • Intervention Type: Drug
  • Participants: 45
  • Start Date: October 7, 2019
Abemaciclib for Treatment of Advanced Bone and Soft Tissue Sarcoma Identified as Having CDK Pathway Alteration
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 2
  • Intervention Type: Genetic
  • Participants: 90
  • Start Date: July 24, 2019
A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR™ T Cells in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
Clinical Trial
  • Status: Recruiting
  • Participants: 3362
  • Start Date: May 29, 2019
Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 1/Phase 2
  • Intervention Type: Drug, Radiation, Procedure
  • Participants: 19
  • Start Date: May 21, 2019
Induction Paclitaxel Followed by Concurrent Paclitaxel and Radiation Therapy for Cutaneous Angiosarcoma
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 2
  • Intervention Type: Device
  • Participants: 300
  • Start Date: March 13, 2019
PROactive Evaluation of Function to Avoid CardioToxicity
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 1
  • Intervention Type: Drug
  • Participants: 27
  • Start Date: March 13, 2019
A Phase 1B Study of PTC596 in Combination With Dacarbazine in Patients With Locally Recurrent, Unresectable or Metastatic Relapsed/Refractory Leiomyosarcoma
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 1/Phase 2
  • Intervention Type: Drug
  • Participants: 143
  • Start Date: August 29, 2018
A Phase Ib/II Study of APG-115 in Combination With Pembrolizumab in Patients With Unresectable or Metastatic Melanomas or Advanced Solid Tumors
Clinical Trial
  • Status: Active, not recruiting
  • Phase: Phase 2
  • Intervention Type: Drug, Procedure
  • Participants: 98
  • Start Date: May 9, 2018
A Phase II Trial of ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma Osteosarcoma, Ewing's Sarcoma, and Small Cell Lung Cancer
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 1
  • Intervention Type: Genetic
  • Participants: 250
  • Start Date: November 22, 2017
Long Term Follow-Up of Participants Exposed to GSK3377794 (NY-ESO-1c259 T), a Genetically Engineered NY-ESO-1 Specific T Cell Receptor
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 1
  • Intervention Type: Drug, Radiation
  • Participants: 46
  • Start Date: November 3, 2017
A Phase Ib Trial of Neoadjuvant AMG 232 (KRT-232) Concurrent With Preoperative Radiotherapy in Wild-Type P53 Soft Tissue Sarcoma (STS)
Clinical Trial
  • Status: Recruiting
  • Participants: 1000
  • Start Date: April 28, 2017
Multi-Institutional Registry for Malignant Peripheral Nerve Sheath Tumors
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 2
  • Intervention Type: Biological, Drug
  • Participants: 62
  • Start Date: March 3, 2017
A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Alveolar Soft Part Sarcoma
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 2
  • Intervention Type: Genetic
  • Participants: 20
  • Start Date: December 6, 2016
A Pilot Study of NY-ESO-1ᶜ²⁵⁹T Cells in Subjects With Advanced Myxoid/ Round Cell Liposarcoma
Clinical Trial
  • Status: Terminated
  • Phase: Phase 1
  • Intervention Type: Drug, Other
  • Participants: 11
  • Start Date: September 13, 2016
A Phase I/II Clinical Trial of Dose-Escalating DHEA in Synovial Sarcoma Patients
Clinical Trial
  • Status: Active, not recruiting
  • Phase: Phase 2
  • Intervention Type: Drug
  • Participants: 73
  • Start Date: February 22, 2016
A Non-Inferiority Study of Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 2
  • Intervention Type: Drug
  • Participants: 250
  • Start Date: December 22, 2015
A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma
Clinical Trial
  • Status: Completed
  • Phase: Phase 2
  • Intervention Type: Drug
  • Participants: 56
  • Start Date: April 8, 2015
A Phase II Study of Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy
Clinical Trial
  • Status: Terminated
  • Phase: Phase 2
  • Intervention Type: Other, Device
  • Participants: 9
  • Start Date: February 3, 2014
Tumor Ablation in Metastatic Sarcoma Stable on Chemotherapy
Clinical Trial
  • Status: Completed
  • Phase: Phase 2
  • Intervention Type: Drug
  • Participants: 80
  • Start Date: March 2009
Determination of Tumor Response Rate by RECIST and FDG-PET Criteria to Dacarbazine in Metastatic Soft Tissue and Bone Sarcoma

All Publications
View All


  • Journal: Cancer drug resistance (Alhambra, Calif.)
  • Published —
PHGDH as a mechanism for resistance in metabolically-driven cancers.

Contact

Saint Louis, MO 63110, US

Affiliations

  • Barnes Jewish Hospital
  • Barnes-Jewish West County Hospital
  • Christian Hospital Northeast
  • Barnes-Jewish St Peters Hospital

Credentials

  • Graduate InstitutionUniversity Of Alabama School Of Medicine
    2005
  • Licenses
    Internal Medicine in MO
  • Board Certifications
    Medical Oncology
    Internal Medicine

Insurance

Contact them to find out if they accept your insurance plan.